KBC Group’s Coherus Oncology CHRS Stock Holding History

KBC Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,736	Closed	-$18K	–	1869
2023 Q3	$18K	Sell	4,736 -763	-14%	-$3.52K	﹤0.01%	1891
2023 Q2	$23K	Hold	5,499	–	–	﹤0.01%	1461
2023 Q1	$38K	Hold	5,499	–	–	﹤0.01%	1434
2022 Q4	$44K	Hold	5,499	–	–	﹤0.01%	1418
2022 Q3	$53K	Hold	5,499	–	–	﹤0.01%	1378
2022 Q2	$40K	Buy	+5,499	New	+$47.8K	﹤0.01%	1458
2022 Q1	–	Sell	-35,429	Closed	-$565K	–	1269
2021 Q4	$565K	Sell	35,429 -1,521	-4%	-$26.6K	﹤0.01%	837
2021 Q3	$594K	Sell	36,950 -37,776	-51%	-$554K	﹤0.01%	831
2021 Q2	$1.03M	Buy	74,726 +10,594	+17%	+$150K	﹤0.01%	873
2021 Q1	$936K	Buy	+64,132	New	+$1.09M	﹤0.01%	890
2020 Q4	–	Sell	-61,168	Closed	-$1.12M	–	1264
2020 Q3	$1.12M	Hold	61,168	–	–	﹤0.01%	793
2020 Q2	$1.09M	Buy	+61,168	New	+$1.04M	﹤0.01%	806

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KBC Group's CHRS Position: Q4 2023 in Review

KBC Group sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 4,736 shares — an estimated $18K sold.

KBC Group first reported a position in CHRS in Q2 2020 and held it in 12 quarters. The position peaked at $1.12M in Q3 2020. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

KBC Group reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
KBC Group sold 4,736 Coherus Oncology shares in Q4 2023, an estimated $18K.
KBC Group first reported a position in Coherus Oncology in Q2 2020 and held it in 12 quarters.
KBC Group's Coherus Oncology position peaked at $1.12M in Q3 2020.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on KBC Group's 13F filing for Q4 2023, filed 13 Feb 2024.